Literature DB >> 22924614

Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1.

Phalguni Gupta1, Carol Lackman-Smith, Beth Snyder, Deena Ratner, Lisa C Rohan, Dorothy Patton, Bharat Ramratnam, Alexander M Cole.   

Abstract

Microbicides have been evaluated mostly against cell-free HIV-1. Because semen contains both cell-free and cell-associated HIV-1, HIV-1 transmission could occur via either or both sources. Therefore, it is important to examine the antiviral activity of microbicides against cell-associated HIV-1. The cyclic antimicrobial peptide retrocyclin RC-101 has been shown previously to have antiviral activity against cell-free HIV-1, with no associated cellular toxicity. In this article we have examined the antiviral activity of RC-101 against cell-associated HIV-1. The results demonstrate potent antiviral activity of RC-101 against cell-cell HIV-1 transmission in both CD4-dependent and CD4-independent assays against CCR5- and CXCR4-tropic HIV-1, with no cellular toxicity. Furthermore, this antiviral activity was retained in the presence of human seminal plasma. The potent antiviral activity of RC-101 against cell-associated HIV-1 reported here, and the previously reported antiviral activity in cervical tissues, suggest that RC-101 is an excellent and promising microbicide candidate against HIV-1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22924614      PMCID: PMC3552163          DOI: 10.1089/AID.2012.0135

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  31 in total

1.  Seminal plasma induces programmed cell death in cultured peripheral blood mononuclear cells.

Authors:  Mari Okamoto; Randall Byrn; Robert C Eyre; Tom Mullen; Paul Church; Ann A Kiessling
Journal:  AIDS Res Hum Retroviruses       Date:  2002-07-20       Impact factor: 2.205

2.  The theta-defensin, retrocyclin, inhibits HIV-1 entry.

Authors:  Carsten Münk; Ge Wei; Otto O Yang; Alan J Waring; Wei Wang; Teresa Hong; Robert I Lehrer; Nathaniel R Landau; Alexander M Cole
Journal:  AIDS Res Hum Retroviruses       Date:  2003-10       Impact factor: 2.205

Review 3.  Inhibiting sexual transmission of HIV-1 infection.

Authors:  Robin J Shattock; John P Moore
Journal:  Nat Rev Microbiol       Date:  2003-10       Impact factor: 60.633

4.  Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity.

Authors:  R W Buckheit; R Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  1991-03       Impact factor: 2.205

5.  Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product.

Authors:  A B Sassi; M R Cost; A L Cole; A M Cole; D L Patton; P Gupta; L C Rohan
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

6.  Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates.

Authors:  M W Cloyd; B E Moore
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

7.  Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team.

Authors:  M Gross; S E Holte; M Marmor; A Mwatha; B A Koblin; K H Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2000-08-01       Impact factor: 3.731

8.  Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1.

Authors:  Alexander M Cole; Teresa Hong; Lee Ming Boo; Tung Nguyen; Chengquan Zhao; Greg Bristol; Jerome A Zack; Alan J Waring; Otto O Yang; Robert I Lehrer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

9.  Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system.

Authors:  Phalguni Gupta; Kelly B Collins; Deena Ratner; Simon Watkins; Gregory J Naus; Daniel V Landers; Bruce K Patterson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques.

Authors:  Alexander M Cole; Dorothy L Patton; Lisa C Rohan; Amy L Cole; Yvonne Cosgrove-Sweeney; Nicole A Rogers; Deena Ratner; Alexandra B Sassi; Carol Lackman-Smith; Patrick Tarwater; Bharat Ramratnam; Piotr Ruchala; Robert I Lehrer; Alan J Waring; Phalguni Gupta
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more
  11 in total

1.  MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.

Authors:  Patrick Barnable; Giulia Calenda; Thierry Bonnaire; Radhika Menon; Keith Levendosky; Agegnehu Gettie; James Blanchard; Michael L Cooney; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa.

Authors:  Colleen R Eade; Amy L Cole; Camila Diaz; Lisa C Rohan; Michael A Parniak; Preston Marx; Patrick M Tarwater; Phalguni Gupta; Alexander M Cole
Journal:  Am J Reprod Immunol       Date:  2012-11-20       Impact factor: 3.886

3.  Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.

Authors:  John W McBride; Nicola Dias; David Cameron; Robin E Offord; Oliver Hartley; Peter Boyd; Vicky L Kett; R Karl Malcolm
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Dmitry S Belov; Pavel O Markov; Alexander V Kurkin; Andrea Altieri; Asim K Debnath
Journal:  J Med Chem       Date:  2020-02-17       Impact factor: 7.446

Review 5.  Modeling mucosal cell-associated HIV type 1 transmission in vitro.

Authors:  Deborah J Anderson
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

6.  A synthetic antimicrobial peptide BTD-S expressed in Arabidopsis thaliana confers enhanced resistance to Verticillium dahliae.

Authors:  Feng Li; Hao Shen; Ming Wang; Kai Fan; Noreen Bibi; Mi Ni; Shuna Yuan; Xuede Wang
Journal:  Mol Genet Genomics       Date:  2016-04-30       Impact factor: 3.291

7.  Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.

Authors:  Francesca Curreli; Young Do Kwon; Hongtao Zhang; Daniel Scacalossi; Dmitry S Belov; Artur A Tikhonov; Ivan A Andreev; Andrea Altieri; Alexander V Kurkin; Peter D Kwong; Asim K Debnath
Journal:  J Med Chem       Date:  2015-08-28       Impact factor: 7.446

8.  Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.

Authors:  Francesca Curreli; Dmitry S Belov; Young Do Kwon; Ranjith Ramesh; Anna M Furimsky; Kathleen O'Loughlin; Patricia C Byrge; Lalitha V Iyer; Jon C Mirsalis; Alexander V Kurkin; Andrea Altieri; Asim K Debnath
Journal:  Eur J Med Chem       Date:  2018-05-12       Impact factor: 6.514

9.  Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Evgeny A Spiridonov; Dmitry S Belov; Andrea Altieri; Alexander V Kurkin; Asim K Debnath
Journal:  Bioorg Med Chem       Date:  2021-01-08       Impact factor: 3.641

Review 10.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.